BioCardia takes a new and comprehensive approach to heart failure

We are a clinical-stage regenerative medicine company developing novel therapies to improve the lives of patients suffering from cardiovascular diseases with large unmet medical needs.

Read More

Discover us

Financials & Filings

Review our corporate financial reports and SEC filings

Press Releases

Read about our latest company milestones

Clinical Trials

Complete Questionnaire to find out if you or a loved one qulifies for our CardiAMP Heart Failure Study

Product Pipeline

Learn about our product development programs and obtain an at-a-glance view of their current status

Products

Helix Biotherapeutic Delivery System

Morph Access Products

News

28 Oct

Cardiology Today

Ongoing trial assessing novel assay to determine response to cardiac regenerative therapy
Read More
11 May

University of Minnesota

Investigational Therapy Exploring Treatment of Heart Failure Seeks to Stimulate Body’s Natural Healing Response
Read More
16 Apr

Saint Joseph Mercy

St. Joseph Mercy Ann Arbor to perform clinical trial using stem cells to treat congestive heart failure
Read More
31 Jan

BioWorld Med Tech

Biocardia wins IDE for cell therapy as treatment for angina
Read More
03 Oct

BioWorld Med Tech

Biocardia presses on with Cardiamp pivotal trial to treat patients with heart failure
Read More
26 May

Med Latest

BioCardia® Helix Results in Higher Stem Cell Retention in Myocardium
Read More
24 May

Fox 47

UW Health trial involves injecting stem cells into patients with heart failure
Read More
18 Apr

Medical press

First participant treated in trial of stem-cell therapy for heart failure
Read More
05 Mar

Cardiology today

First patient treated in trial of novel cell therapy
Read More

press releases

16 Sep
2019 BioCardia Announces Positive DSMB Recommendation to Continue Phase 3 Pivotal CardiAMP Heart Failure Study as Planned
21 Aug
2019 BioCardia Reports 2019 Second Quarter Financial Results and Business Highlights
07 Aug
2019 BioCardia Announces Issuance of European Patent for Breakthrough Diagnostic Assay for Patient Selection Prior to Cardiac Cell Therapy Delivery
06 Aug
2019 BioCardia Announces Closing of $10.0 Million Public Offering
02 Aug
2019 BioCardia Announces Pricing of $10.0 Million Public Offering and Uplisting to NASDAQ
25 Jul
2019 BioCardia Signs Exclusive Development Agreement with AstraZeneca
Have questions?
CALL US NOW
: (800) 624-1179
Have questions?
EMAIL US NOW
: info@biocardia.com

biocardia takes a new and comprehensive
approach to heart failure

By introducing patient screening and highly-efficient delivery to stem cell therapy, the company seeks to increase the likelihood of treatment success, enabling more patients to return to the things they love.
CLINICAL TRIALS